NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC reduced its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 4.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 837,368 shares of the company’s stock after selling 35,169 shares during the period. TimesSquare Capital Management LLC’s holdings in NewAmsterdam Pharma were worth $23,815,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Mather Group LLC. purchased a new position in NewAmsterdam Pharma in the 3rd quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in NewAmsterdam Pharma in the 3rd quarter worth about $30,000. Wolverine Asset Management LLC purchased a new stake in NewAmsterdam Pharma in the 3rd quarter valued at about $69,000. KLP Kapitalforvaltning AS increased its stake in shares of NewAmsterdam Pharma by 51.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 9,100 shares of the company’s stock valued at $165,000 after acquiring an additional 3,100 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $199,500.00. Following the sale, the insider directly owned 73,481 shares of the company’s stock, valued at $2,443,243.25. This trade represents a 7.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Louise Frederika Kooij sold 75,117 shares of the business’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the transaction, the chief accounting officer directly owned 15,000 shares of the company’s stock, valued at approximately $543,150. This trade represents a 83.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 298,647 shares of company stock valued at $10,236,050. 20.84% of the stock is owned by company insiders.

NewAmsterdam Pharma Trading Down 0.7%

NASDAQ NAMS opened at $34.63 on Monday. The company’s fifty day simple moving average is $34.04 and its 200-day simple moving average is $32.22. The stock has a market cap of $3.93 billion, a P/E ratio of -16.89 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NAMS. HC Wainwright started coverage on NewAmsterdam Pharma in a research report on Monday, October 20th. They issued a “buy” rating and a $52.00 target price on the stock. Stifel Nicolaus lifted their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Needham & Company LLC increased their price objective on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.